MMSET: Role and Therapeutic Opportunities in Multiple Myeloma | Zendy

Zhigang Xie | Zendy; Wee Joo Chng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma

Author(s) -

Zhigang Xie,

Wee Joo Chng

Publication year - 2014

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2014/636514

Subject(s) - chromosomal translocation , multiple myeloma , cancer research , fibroblast growth factor receptor 3 , histone , biology , fibroblast growth factor receptor , pathogenesis , fibroblast growth factor , gene , receptor , medicine , bioinformatics , immunology , genetics

Recurrent chromosomal translocations are central to the pathogenesis, diagnosis, and prognosis of hematologic malignancies. The translocation t(4; 14)(p16; q32) is one of the most common translocations in multiple myeloma (MM) and is associated with very poor prognosis. The t(4; 14) translocation leads to the simultaneous overexpression of two genes, FGFR3 (fibroblast growth factor receptor 3) and MMSET (multiple myeloma SET domain), both of which have potential oncogenic activity. However, approximately 30% of t(4; 14) MM patients do not express FGFR3 and have poor prognosis irrespective of FGFR3 expression, whereas MMSET overexpression is universal in t(4; 14) cases. In this review, we provide an overview of recent findings regarding the oncogenic roles of MMSET in MM and its functions on histone methylation. We also highlight some of MMSET partners and its downstream signalling pathways and discuss the potential therapeutics targeting MMSET.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research